# A Clinical Study of PA5 in Patients With Advanced Solid Tumors

> **NCT07702162** · PHASE1 · RECRUITING · sponsor: **Chongqing Peg-Bio Biopharm Co., Ltd.** · enrollment: 49 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Cancer

## Interventions

- **BIOLOGICAL:** PA5

## Key facts

- **NCT ID:** NCT07702162
- **Lead sponsor:** Chongqing Peg-Bio Biopharm Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-14
- **Primary completion:** 2027-02-02
- **Final completion:** 2027-06-04
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2026-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07702162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07702162, "A Clinical Study of PA5 in Patients With Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07702162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*